Answers are grounded in this paper and cite their sources.
Background The benefits and side effects of pharmacological treatments for dementia are inherently difficult to qualify. Little is known about how treatments are discussed in practice, despite the impact of discissions on the decision to take treatments, understanding of medications, and adherence. This study sought to understand how the benefits and side effects of treatments are communicated in clinical encounters. Methods Twenty-nine memory assessment clinic consultations across two UK NHS Trusts were video recorded, involving ten clinicians, 29 patients and 32 relatives or supporters. Consultations were analysed using content analysis to identify patterns in communication. Results Findings indicted that whilst there were some common approaches to presenting treatments, discussions varied in ways that could influence patient outcomes. In 26 of the 29 consultations benefits of treatments were presented as symptom management, most commonly with a focus on memory and cognition. In 13 of the 29 consultations clinicians specified that treatment was not curative. One third of consultations, at some point, suggested treatments may be disease modifying, and around half referred to symptom reduction or delay. Side effects were discussed in 26 of 29 consultations, often with verbal qualifiers indicating the certainty or likelihood of the effects. The side effect profile was commonly described as not serious/minimising . How treatments worked was described in 13 consultations, with eight presenting this in a patient friendly way. Discussions of risk/benefit occurred in half of the consultations. Conclusions Our analysis showed positive framing of the benefits of dementia treatments by clinicians. There was a lack of consistency in the way that both benefits and side effects were described. Recommendations include guidance for discussing dementia medications to promote understanding and informed decision making including (1) caution about using leading language (2) ensuring consistent and transparent communication and (3) employing evidence-based patient decision aids where appropriate. Clinical trial number Not applicable.
No takes yet. Share an insight, caveat, or question.
Smith et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: